Glass Wealth Management Co LLC Sells 260 Shares of Sanofi (NASDAQ:SNY)

Glass Wealth Management Co LLC reduced its position in shares of Sanofi (NASDAQ:SNY) by 0.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 30,845 shares of the company’s stock after selling 260 shares during the quarter. Glass Wealth Management Co LLC’s holdings in Sanofi were worth $1,778,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi in the 3rd quarter worth $29,000. POM Investment Strategies LLC bought a new stake in Sanofi during the second quarter valued at about $25,000. Concord Wealth Partners grew its holdings in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. Arrow Financial Corp purchased a new stake in Sanofi in the second quarter worth about $35,000. Finally, Fortitude Family Office LLC raised its stake in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Up 0.3 %

Shares of SNY opened at $47.97 on Monday. The business’s 50 day moving average is $54.65 and its 200 day moving average is $52.23. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a market capitalization of $121.74 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the business posted $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Research analysts expect that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.